Naltrexone-bupropion is a combination weight-management medicine with a different mechanism and restriction profile from GLP-1-related treatment. Its oral presentation can be appealing, but the major questions include opioid use, seizure risk, blood pressure, psychiatric history and how response will be reviewed.
The combination is known as Contrave in the United States and Mysimba in the European Union. These are jurisdiction-specific product records, not permission to combine separate prescriptions independently. This guide uses current hosted US information, EMA’s record and review, and original COR-I evidence checked on 3 October 2026.
What the combination is intended to do
Contrave’s US label on DailyMed describes an adult weight-management indication with reduced-calorie eating and increased activity in specified populations. Naltrexone is an opioid antagonist; bupropion affects norepinephrine and dopamine signaling. The precise neurochemical effects responsible for weight reduction are not fully understood.
The mechanism should not be turned into a claim that the medicine fixes every form of emotional eating or treats an eating disorder. A person’s relationship with food may need assessment and support beyond a weight-management prescription. The label itself includes important restrictions related to eating-disorder and seizure history.
The fixed combination has its own formulation and evidence. Using separate products to imitate it can change release characteristics, instructions and exposure. A clinician’s prescription plan should identify the actual approved product or explain a separate decision; this article does not provide a do-it-yourself combination regimen.
The original trial benefit and its limitations
COR-I randomized 1,742 adults with obesity, or overweight with specified complications, to sustained-release combinations or placebo for 56 weeks. The studied NB32 regimen produced mean weight reduction of 6.1%, compared with 1.3% for placebo, alongside diet and exercise advice. Those figures belong to that regimen and analysis.
Only half the participants completed 56 weeks of treatment. The primary analysis included participants with baseline and post-baseline on-treatment weight measurements and used last observation carried forward. This is a major limitation to keep beside the result, not a footnote to omit when comparing a trial percentage.
The study supports a weight-loss effect under the defined conditions. It does not establish the same result for every person or prove a long-term cardiovascular benefit. A statistically favorable weight endpoint is different from an outcomes trial designed to evaluate cardiovascular events. The combination’s ongoing safety assessment matters for that distinction.
Opioid treatment can be a decisive issue
Naltrexone blocks opioid receptors. The US label contraindicates chronic opioid use and acute opioid withdrawal. Starting treatment in someone using opioids can precipitate withdrawal, and blockade can interfere with opioid pain treatment. These concerns include some medicines used for pain and treatment of opioid dependence.
Tell the prescriber about every opioid-containing product and any planned procedure that may need pain management. Do not attempt to overcome blockade by taking more opioid medication. If urgent pain treatment is needed, the treating team should know about the combination.
Stopping or restarting around opioid use requires a specific clinical plan. An article cannot select a washout interval or judge when withdrawal risk has resolved. Bring the product name and timing to the assessing clinician. This interaction should be considered before treatment begins, rather than discovered during a pain emergency.
Seizure risk requires a detailed medication history
The label lists seizure disorder and certain related risks among contraindications, including anorexia nervosa or bulimia and abrupt discontinuation of specified sedating substances or medicines. Other bupropion-containing products should not be added. These restrictions need a precise history rather than a casual question about whether someone has ever felt dizzy.
Alcohol use, sedating medicines and planned withdrawal from them should be discussed honestly. Do not abruptly stop such products to make a weight-management prescription appear suitable. The care team needs to understand the actual situation and coordinate any changes.
Other medicines can affect seizure threshold or bupropion exposure. A pharmacist’s complete interaction review is useful, including prescriptions from different specialists and nonprescription products. An oral route should not make this seem like a routine supplement choice.
Blood pressure and psychiatric monitoring matter
Uncontrolled hypertension is a contraindication in the US label, and blood pressure and heart rate require attention during treatment. Losing weight does not guarantee that every medication effect on these measures is favorable. The immediate treatment effect and the longer-term health goal are separate questions.
Bupropion-containing products carry important psychiatric warnings, including the antidepressant boxed warning about suicidal thoughts and behaviors in young people and young adults. Discuss current symptoms, psychiatric history and other medicines with the prescriber. New concerning mood or behavioral changes need prompt contact; immediate safety concerns require urgent help.
A trial reporting no excess of a particular psychiatric event does not erase the label’s warning or establish safety for every excluded population. The full benefit-risk assessment uses more than one study. Ask what symptoms should trigger contact and who will monitor them.
European long-term cardiovascular questions remain visible
EMA’s Mysimba product record provides the EU indication and instructions. The completed 2025 safety review states that available information was insufficient to fully characterize cardiovascular safety beyond 12 months. It imposed further study and reinforced annual benefit-risk assessment and weight-maintenance requirements.
The regulator’s action should not be summarized as either proof of long-term harm or proof that all long-term concerns are settled. Authorisation can continue with additional conditions and evidence requirements. The original review documents identify what remains uncertain and what follow-up is expected.
This also shows why product status needs a date. A treatment approved years earlier can receive important new reassessment instructions. A review of the medicine should keep those instructions alongside the older efficacy evidence rather than treating approval as a one-time event.
Set a response review before starting
Ask which local stopping or reassessment criteria apply, when the team will evaluate response and how blood pressure, mood and adverse effects will be assessed. A meaningful improvement has to be balanced against burdens and restrictions. A favorable average does not justify indefinite continuation without review.
Our appointment guide helps prepare the medical and medication history. The evidence-design guide explains why longer-term safety may require additional kinds of data beyond an initial efficacy trial.
Naltrexone-bupropion is best considered as an exact combination product within a coordinated care plan. Its distinct restrictions are not incidental details added after a convenience decision. They are central to whether the potential benefit is usable and worth continuing.



